Recurrence of ANCA-associated vasculitis following renal transplantation in the modern era of immunosupression

M. Gera, M. D. Griffin, Ulrich Specks, N. Leung, Mark D Stegall, Fernando Custodio Fervenza

Research output: Contribution to journalArticle

69 Citations (Scopus)

Abstract

Progressive glomerulonephritis and attendant end-stage renal disease (ESRD) result from antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis. The optimum time of kidney transplantation in patients with ESRD due to ANCA-associated vasculitis (AAV) and the risk of renal or nonrenal recurrence of vasculitis after transplantation are unknown. To answer some of these questions, we followed 35 transplant recipients with diagnoses of microscopic polyangiitis (20 patients) and Wegener's granulomatosis (15 patients). The median time from diagnosis to transplantation was 25 months with all patients being in clinical remission. Fifteen patients were ANCA-positive at time of the transplant with 13 preemptive transplants. The most common immunosuppressive strategy included antibody induction, corticosteroid, mycophenolate mofetil, and tacrolimus with acute rejection occurring in eight cases. Overall and death-censored graft survivals were 94 and 100%, respectively, 5 years post-transplantation. Nonrenal relapse occurred in three patients with a satisfactory response to treatment. No clear risk factor to relapse emerged and no detrimental effect to renal function was found. We conclude that transplantation should be considered as the treatment of choice for ESRD due to AAV. Potent antirejection regimes are well tolerated in these patients, are associated with a low risk of recurrence and an absence of AAV-related graft dysfunction.

Original languageEnglish (US)
Pages (from-to)1296-1301
Number of pages6
JournalKidney International
Volume71
Issue number12
DOIs
StatePublished - Jun 2007

Fingerprint

Antineutrophil Cytoplasmic Antibodies
Vasculitis
Kidney Transplantation
Recurrence
Transplantation
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Chronic Kidney Failure
Transplants
Microscopic Polyangiitis
Mycophenolic Acid
Kidney
Granulomatosis with Polyangiitis
Tacrolimus
Graft Survival
Immunosuppressive Agents
Glomerulonephritis
Adrenal Cortex Hormones
Antibodies
Therapeutics

Keywords

  • ANCA
  • Kidney transplantation
  • Microscopic polyangiitis
  • Relapse
  • Vasculitis
  • Wegener

ASJC Scopus subject areas

  • Nephrology

Cite this

Recurrence of ANCA-associated vasculitis following renal transplantation in the modern era of immunosupression. / Gera, M.; Griffin, M. D.; Specks, Ulrich; Leung, N.; Stegall, Mark D; Fervenza, Fernando Custodio.

In: Kidney International, Vol. 71, No. 12, 06.2007, p. 1296-1301.

Research output: Contribution to journalArticle

@article{39af1d68976149a3a7b4046bcfded7e3,
title = "Recurrence of ANCA-associated vasculitis following renal transplantation in the modern era of immunosupression",
abstract = "Progressive glomerulonephritis and attendant end-stage renal disease (ESRD) result from antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis. The optimum time of kidney transplantation in patients with ESRD due to ANCA-associated vasculitis (AAV) and the risk of renal or nonrenal recurrence of vasculitis after transplantation are unknown. To answer some of these questions, we followed 35 transplant recipients with diagnoses of microscopic polyangiitis (20 patients) and Wegener's granulomatosis (15 patients). The median time from diagnosis to transplantation was 25 months with all patients being in clinical remission. Fifteen patients were ANCA-positive at time of the transplant with 13 preemptive transplants. The most common immunosuppressive strategy included antibody induction, corticosteroid, mycophenolate mofetil, and tacrolimus with acute rejection occurring in eight cases. Overall and death-censored graft survivals were 94 and 100{\%}, respectively, 5 years post-transplantation. Nonrenal relapse occurred in three patients with a satisfactory response to treatment. No clear risk factor to relapse emerged and no detrimental effect to renal function was found. We conclude that transplantation should be considered as the treatment of choice for ESRD due to AAV. Potent antirejection regimes are well tolerated in these patients, are associated with a low risk of recurrence and an absence of AAV-related graft dysfunction.",
keywords = "ANCA, Kidney transplantation, Microscopic polyangiitis, Relapse, Vasculitis, Wegener",
author = "M. Gera and Griffin, {M. D.} and Ulrich Specks and N. Leung and Stegall, {Mark D} and Fervenza, {Fernando Custodio}",
year = "2007",
month = "6",
doi = "10.1038/sj.ki.5002244",
language = "English (US)",
volume = "71",
pages = "1296--1301",
journal = "Kidney International",
issn = "0085-2538",
publisher = "Nature Publishing Group",
number = "12",

}

TY - JOUR

T1 - Recurrence of ANCA-associated vasculitis following renal transplantation in the modern era of immunosupression

AU - Gera, M.

AU - Griffin, M. D.

AU - Specks, Ulrich

AU - Leung, N.

AU - Stegall, Mark D

AU - Fervenza, Fernando Custodio

PY - 2007/6

Y1 - 2007/6

N2 - Progressive glomerulonephritis and attendant end-stage renal disease (ESRD) result from antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis. The optimum time of kidney transplantation in patients with ESRD due to ANCA-associated vasculitis (AAV) and the risk of renal or nonrenal recurrence of vasculitis after transplantation are unknown. To answer some of these questions, we followed 35 transplant recipients with diagnoses of microscopic polyangiitis (20 patients) and Wegener's granulomatosis (15 patients). The median time from diagnosis to transplantation was 25 months with all patients being in clinical remission. Fifteen patients were ANCA-positive at time of the transplant with 13 preemptive transplants. The most common immunosuppressive strategy included antibody induction, corticosteroid, mycophenolate mofetil, and tacrolimus with acute rejection occurring in eight cases. Overall and death-censored graft survivals were 94 and 100%, respectively, 5 years post-transplantation. Nonrenal relapse occurred in three patients with a satisfactory response to treatment. No clear risk factor to relapse emerged and no detrimental effect to renal function was found. We conclude that transplantation should be considered as the treatment of choice for ESRD due to AAV. Potent antirejection regimes are well tolerated in these patients, are associated with a low risk of recurrence and an absence of AAV-related graft dysfunction.

AB - Progressive glomerulonephritis and attendant end-stage renal disease (ESRD) result from antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis. The optimum time of kidney transplantation in patients with ESRD due to ANCA-associated vasculitis (AAV) and the risk of renal or nonrenal recurrence of vasculitis after transplantation are unknown. To answer some of these questions, we followed 35 transplant recipients with diagnoses of microscopic polyangiitis (20 patients) and Wegener's granulomatosis (15 patients). The median time from diagnosis to transplantation was 25 months with all patients being in clinical remission. Fifteen patients were ANCA-positive at time of the transplant with 13 preemptive transplants. The most common immunosuppressive strategy included antibody induction, corticosteroid, mycophenolate mofetil, and tacrolimus with acute rejection occurring in eight cases. Overall and death-censored graft survivals were 94 and 100%, respectively, 5 years post-transplantation. Nonrenal relapse occurred in three patients with a satisfactory response to treatment. No clear risk factor to relapse emerged and no detrimental effect to renal function was found. We conclude that transplantation should be considered as the treatment of choice for ESRD due to AAV. Potent antirejection regimes are well tolerated in these patients, are associated with a low risk of recurrence and an absence of AAV-related graft dysfunction.

KW - ANCA

KW - Kidney transplantation

KW - Microscopic polyangiitis

KW - Relapse

KW - Vasculitis

KW - Wegener

UR - http://www.scopus.com/inward/record.url?scp=34250017999&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34250017999&partnerID=8YFLogxK

U2 - 10.1038/sj.ki.5002244

DO - 10.1038/sj.ki.5002244

M3 - Article

C2 - 17410100

AN - SCOPUS:34250017999

VL - 71

SP - 1296

EP - 1301

JO - Kidney International

JF - Kidney International

SN - 0085-2538

IS - 12

ER -